Revolutionizing Infection Control: The Role of Bacteriophage Therapy in Combating Antimicrobial Resistance

Jorge Angel Velasco Espinal, Jorge Arizmendi García, José Eduardo Velasco Espinal, Katerin Alvarado Echenoa, Daniel Alberto Madrid Gonzalez, Guadalupe Angeles Chimal, Alexa Fernanda Uriostegui Navarro and Ariana Itzel Olvera Dueñas
Additional contact information
Jorge Angel Velasco Espinal: Universidad del Valle de Cuernavaca
Jorge Arizmendi García: Universidad del Valle de Cuernavaca
José Eduardo Velasco Espinal: Universidad Latinoamericana
Katerin Alvarado Echenoa: Universidad El Bosque
Daniel Alberto Madrid Gonzalez: Universidad del Valle de Cuernavaca
Guadalupe Angeles Chimal: Universidad del Valle de Cuernavaca
Alexa Fernanda Uriostegui Navarro: Universidad del Valle de Cuernavaca
Ariana Itzel Olvera Dueñas: Universidad del Valle de Cuernavaca

International Journal of Research and Innovation in Social Science, 2025, vol. 9, issue 3s, 5433-5450

Abstract: The escalating threat of antimicrobial resistance (AMR) has intensified the global pursuit of innovative therapeutic alternatives to conventional antibiotics. Bacteriophage therapy, a century-old approach that employs viruses to selectively target and lyse bacterial pathogens, has re-emerged as a credible strategy for managing multi-drug resistant (MDR) infections that no longer respond to traditional treatments. This documentary research examines the current relevance, clinical feasibility, and practical implications of integrating bacteriophage therapy into modern infection control frameworks. A purposive, systematic review of thirty peer-reviewed sources was conducted, encompassing empirical studies, clinical trials, compassionate-use reports, and expert analyses published primarily within the last fifteen years. The evidence was analyzed to identify infection types most frequently treated, geographical trends in research and application, clinical outcomes, development stages, administration routes, and formulation strategies. The results confirm that bacteriophage therapy demonstrates considerable therapeutic potential, with the majority of documented interventions reporting complete or partial resolution of resistant infections. Notably, Pseudomonas aeruginosa and Staphylococcus aureus remain the primary targets of phage-based interventions, while Europe and North America lead in advancing clinical development and translational research. The evolution of phage formulations from natural isolates to sophisticated genetically engineered constructs reflects the field’s adaptability and technological progress. Despite these advances, critical barriers persist, including regulatory challenges, the limited number of Phase III trials, and the need for robust phage banks and standardized clinical protocols. This study concludes that bacteriophage therapy represents a viable adjunct or alternative to conventional antimicrobials, contributing meaningful theoretical and practical insights to the field. Its successful integration into mainstream infection control strategies will depend on sustained interdisciplinary research, regulatory innovation, and equitable access to ensure its full potential is realized in the global fight against AMR.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.rsisinternational.org/journals/ijriss/ ... sue-3s/5433-5450.pdf (application/pdf)
https://rsisinternational.org/journals/ijriss/arti ... icrobial-resistance/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bcp:journl:v:9:y:2025:i:3s:p:5433-5450

Access Statistics for this article

International Journal of Research and Innovation in Social Science is currently edited by Dr. Nidhi Malhan

More articles in International Journal of Research and Innovation in Social Science from International Journal of Research and Innovation in Social Science (IJRISS)
Bibliographic data for series maintained by Dr. Pawan Verma ().